ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
-1,03%
Bitcoin
62 872,25
6,34%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Viking Therapeutics Inc (VKTX)

  7. Viking Therapeutics Inc (VKTX) Actualités

VKTX Viking Therapeutics Inc

77,09
1,33 (1,76%)
Après les heures de négociation
Dernière mise à jour : 00:25:55
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Viking Therapeutics Inc VKTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
1,33 1,76% 77,09 00:25:55
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
74,40 72,88 77,68 76,97 75,76
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
24/4/202422:05PRNUSViking Therapeutics Reports First Quarter 2024 Financial..
24/4/202413:31IHMARKETNEWSU.S. Futures Display Mixed Results Amid Earnings, WTI and..
17/4/202422:05PRNUSViking Therapeutics to Report Financial Results for First..
26/3/202412:03PRNUSViking Therapeutics Announces Results from Phase 1 Clinical..
05/3/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202401:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:52EDGAR2Form 8-K - Current report
04/3/202422:45PRNUSViking Therapeutics Announces Closing of Public Offering of..
01/3/202422:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/2/202402:50PRNUSViking Therapeutics Announces Pricing of $550 Million Public..
27/2/202423:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/2/202422:19PRNUSViking Therapeutics Announces Proposed Public Offering of..
27/2/202413:04EDGAR2Form 8-K - Current report
27/2/202413:03PRNUSViking Therapeutics Announces Positive Top-Line Results from..
10/2/202402:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:01EDGAR2Form 144 - Report of proposed sale of securities
09/2/202401:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202401:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202422:56EDGAR2Form 144 - Report of proposed sale of securities
08/2/202422:33EDGAR2Form 144 - Report of proposed sale of securities
07/2/202423:33EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/2/202423:24EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/2/202422:09EDGAR2Form 8-K - Current report
07/2/202422:05PRNUSViking Therapeutics Reports Fourth Quarter and Year-End 2023..
01/2/202402:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202423:32EDGAR2Form 144 - Report of proposed sale of securities
31/1/202422:05PRNUSViking Therapeutics to Report Financial Results for Fourth..
31/1/202403:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202422:23EDGAR2Form 144 - Report of proposed sale of securities
20/1/202402:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202422:36EDGAR2Form 144 - Report of proposed sale of securities
05/1/202403:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202403:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202403:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202322:02PRNUSViking Therapeutics Presents New Data from Phase 2b VOYAGE..
02/11/202321:03PRNUSViking Therapeutics to Participate at Upcoming Investor..
25/10/202323:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
25/10/202322:24EDGAR2Form 8-K - Current report
25/10/202322:05PRNUSViking Therapeutics Reports Third Quarter 2023 Financial..
23/10/202313:05PRNUSViking Therapeutics Announces Completion of Enrollment in..
18/10/202322:05PRNUSViking Therapeutics to Report Financial Results for Third..
18/10/202315:06IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Analyst..
18/10/202315:03IHMARKETNEWSWednesday’s Wall Street Highlights: ASML, Nvidia, United..
17/10/202322:05PRNUSViking Therapeutics Presents New Data from Phase 1 Clinical..
10/10/202322:05PRNUSViking Therapeutics to Highlight Data from Phase 1 Clinical..
07/9/202322:05PRNUSViking Therapeutics to Participate at Upcoming Investor..
06/9/202313:03PRNUSViking Therapeutics Announces Initiation of Phase 2 VENTURE..
26/7/202323:26EDGAR2Form S-3ASR - Automatic shelf registration statement of..
26/7/202322:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
26/7/202322:23EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
VKTX
Viking Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés